SAN DIEGO, May 26, 2015 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO; "Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, announced today that the company will present at an
upcoming investor event, the Jeffries 2015 Healthcare Conference,
to be held in New York,
June 1 – 4, 2015. Keith Murphy, Chairman and Chief Executive
Officer, will deliver a company presentation and discuss recent key
advances and partnerships.
Details of the presentations are as follows:
Speaker: Keith
Murphy, Chairman and Chief Executive Officer
|
Date/Time:
|
Monday, June 1, 2015,
10 a.m. ET
|
Organovo's 3D bioprinting enables the reproducible, automated
creation of living human tissues that mimic the form and function
of native tissues in the body. The company recently announced
advances in bioprinting of kidney tissue; collaborations with
L'Oreal to produce skin tissue for research and in vitro
toxicity testing; and with Merck to develop multiple new 3D
tissues, as well as to bioprint liver tissues for studies of drug
toxicity; and with Yale School of
Medicine to develop 3-D organ tissues for surgical
transplantation research. Organovo was named one of The World's
Top 10 Most Innovative Companies of 2015 in Health Care by
Fast Company.
An overview of Organovo's 3D bioprinting technology is available
via video presentation at the Company's website:
http://www.organovo.com/investors/investor-overview.
The Jeffries 2015 Healthcare Conference will feature an
extensive range of public and private healthcare companies across
the biopharmaceuticals, life sciences, healthcare services,
healthcare IT and medical technology sectors. This global gathering
of leading executives, institutional investors, private equity
investors and VCs will address near- and long-term investment
opportunities and discuss the mechanisms driving healthcare in the
U.S. and internationally.
For more information about Organovo's participation in industry
events, please visit:
http://www.organovo.com/tissues-services/upcoming-events.
About Organovo Holdings, Inc.
Organovo designs
and creates functional, three-dimensional human tissues for use in
medical research and therapeutic applications. The Company develops
3D human disease models through internal development and in
collaboration with pharmaceutical and academic partners. Organovo's
3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. The company recently launched its initial product of
the planned exVive3DTM portfolio offering, a 3D Human
Liver Tissue for use in Toxicology and other preclinical drug
testing. Additional products are in development, with anticipated
release for an exVive3DTM Human Kidney Tissue in the
latter half of calendar year 2016. The Company also actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
other media outlets. Organovo is changing the shape of medical
research and practice. Learn more at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
Quarterly Report on Form 10-Q filed with the SEC on February 6, 2015. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws of
the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
Sign up for email updates and connect with us
on Twitter (@Organovo).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-to-present-at-jeffries-2015-healthcare-conference-300088064.html
SOURCE Organovo Holdings, Inc.